ClinicalTrials.gg
CompletedNCT04609904LOGOSUpdated Jul 2, 2026Results posted

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

A Phase 3 interventional study of BGF MDI 320/28.8/9.6 μg and BGF MDI 320/14.4/9.6 μg in Asthma, sponsored by AstraZeneca. Completed at 317 sites in 16 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,187
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
4th of 108
2,187 · median 124
Started
2021
with 1 other
Phase 3
51 of 110
3 open now
Registered
99th of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 4th largest by enrollment of the 108 interventional ones that give a count, is one of 2 that started in 2021, is one of 51 in phase 3, and was the 99th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care.

Read the detailed description

This is a randomized, double-blind, double dummy, parallel group, multicenter 24 to 52 week variable length study to assess the efficacy and safety of budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler (MDI) relative to budesonide and formoterol fumarate MDI and Symbicort® pressurized MDI in adult and adolescent participants with inadequately controlled asthma. Approximately 2200 participants will be randomized globally.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 12 to 80 years of age, male and female, \<40 kg/m2; females must be not of or using a form of highly effective .
  2. Documented history of physician-diagnosed asthma > and/or = 1 year prior to V1.
  3. Regularly using a stable daily ICS/LABA regimen (including a stable ICS dose) with medium-to-high ICS doses for at least 4 weeks prior to V1.
  4. ACQ-7 total score ≥1.5 at Visits 1, 3, and 5 (pre-randomization).
  5. % (assessed as an average of the 60 and 30 minute pre-dose assessments) predicted normal at V1, 2, 3, 4, and 5 (pre-randomization)

    • Participants > and/or = 18 years of age: \< 80%
    • Participants 12 to \<18 years of age: \< 90%
  6. FEV1 post-albuterol at V2 or V3 (if repeat needed). • Participants > and/or = 18 years of age: Increase > and/or = 12% and > and/or = 200 mL.

    • Participants 12 to \<18 years of age: Increase =12% either in the 12 months prior to Visit 1 or at Visit 2, or at Visit 3.
    • Note: Even if there is documented history of reversibility, all participants must be assessed for reversibility at Visit 2 (and Visit 3, if reversibility is not demonstrated at Visit 2) to provide reversibility baseline data for characterization.
  7. Willing and, in the opinion of the Investigator, able to adjust current asthma therapy, as required by the protocol.
  8. Demonstrate acceptable MDI/pMDI administration technique.
  9. Received no asthma medication other than run-in BFF MDI BID and albuterol as needed during screening (except for allowed medications as defined in Table 9 and systemic or ICS for the treatment of an asthma exacerbation).
  10. eDiary 14-day compliance ≥70% during screening (defined as completing the daily eDiary for any 10 mornings and any 10 evenings and answering "Yes" to taking 2 puffs of run-in BFF MDI for any 10 mornings and 10 evenings in the last 14 days prior to randomization).
  11. No respiratory infection in the 4 weeks prior to randomization, or asthma exacerbation treated with systemic corticosteroid and/or additional ICS treatment in the 4 weeks prior to randomization.

Exclusion criteria

Exclusion Criteria:

1. Completed treatment for respiratory infection or asthma exacerbation with systemic within 4 weeks of V1.

2a. Participants where, in the opinion of the Investigator, treatment with biological therapy for asthma would be appropriate.

2b. Any marketed or biologics within 3 months or 5 halflives of V1, whichever is longer and must not be used during study duration.

3. Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking \<6 months prior to V1 (including all forms of tobacco, e-cigarettes or other vaping devices, and marijuana).

4. Current evidence of .

5a. Oral and IV corticosteroid use (any dose) within 4 weeks of V1.

5b. Use of systemic corticosteroids for any other reason except for the acute treatment of severe asthma exacerbation is prohibited for the duration of the study.

5c. Depot corticosteroid use for any reason within 3 months of V1.

6. Use of LAMA, either alone or as part of an inhaled combination therapy, in the 12 weeks prior to Visit 1.

7. Use of oral beta2-agonist within 3 months of V1.

8. Use of any immunomodulators or medication within 3 months or 5 half-lives, whichever is longer, and must not be used during the study duration.

9. Narrow angle glaucoma not adequately treated and/or change in vision that may be relevant, in the opinion of the Investigator, within 3 months of Visit 1.

10. Life-threatening asthma defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).

11. Hospitalization for asthma within 2 months of Visit 1.

12. Known history of drug or alcohol abuse within 12 months of Visit 1.

13. Regular use of a nebulizer or a home nebulizer for receiving asthma medications.

14. Using any herbal products by inhalation or nebulizer within 4 weeks of Visit 1 and does not agree to stop during the study duration.

15. Participation in another clinical study with a study intervention administered in the last 30 days or 5 half-lives, whichever is longer. Any other study intervention that is not identified in the protocol is prohibited for use during study duration.

16. Participants with a known to beta2-agonists, corticosteroids, anticholinergics, or any component of the MDI or pMDI.

17. Study Investigators, sub-Investigators, coordinators, and their employees or immediate family members.

18. For women only - currently pregnant (confirmed with positive highly sensitive pregnancy test), breast-feeding, or planned pregnancy during the study or not using acceptable measures, as judged by the Investigator.

Please refer to the study protocol for the complete inclusion and exclusion criteria list

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,187 participants (actual)

Study arms

  • Experimental
    Budesonide, glycopyrronium, and formoterol fumarate (BGF) MDI 320/28.8/9.6 μg

    BGF MDI 320/28.8/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)

    Drug: BGF MDI 320/28.8/9.6 μg

  • Experimental
    BGF MDI 320/14.4/9.6 μg

    BGF MDI 320/14.4/9.6 μg Budesonide, glycopyrronium, and formoterol fumarate (PT010) Metered Dose Inhaler (MDI)

    Drug: BGF MDI 320/14.4/9.6 μg

  • Active comparator
    Budesonide and formoterol fumarate (BFF) MDI 320/9.6 μg

    BFF MDI 320/9.6 μg (Experimental/Comparator) Budesonide and formoterol fumarate (PT009) Metered Dose Inhaler (MDI)

    Drug: BFF MDI 320/9.6 μg

  • Active comparator
    Symbicort®

    Budesonide/ formoterol fumarate pressurized metered dose inhaler (pMDI) 320/9 μg

    Drug: BFF pMDI 320/9 μg

Interventions

  • DrugBGF MDI 320/28.8/9.6 μg

    Drug pages: Budesonide · Glycopyrrolate · Formoterol

    Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler

    Also known as: BGF

  • DrugBGF MDI 320/14.4/9.6 μg

    Drug pages: Budesonide · Glycopyrrolate · Formoterol

    Budesonide, glycopyrronium, and formoterol fumarate metered dose inhaler

    Also known as: BGF

  • DrugBFF MDI 320/9.6 μg

    Drug pages: Budesonide · Formoterol

    Budesonide and formoterol fumarate metered dose inhaler

    Also known as: BFF

  • DrugBFF pMDI 320/9 μg

    Budesonide/formoterol fumarate pressurized metered dose inhaler

    Also known as: Symbicort®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in FEV1 AUC0-3 (L) at Week 24

    Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24. Treatment policy was implemented to handle all intercurrent events (ICEs) with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Week 24

  2. Pooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations

    Rate of severe asthma exacerbations was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). An asthma exacerbation was severe if it resulted in at least 1 of the following: systemic corticosteroids for 3 days, an ER/urgent care visit requiring systemic corticosteroids, a hospitalization, or death related to asthma. Consecutive exacerbations with start/stop days ≤7 days apart were considered the same event. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Up to 52 Weeks

Secondary outcomes

  1. Change From Baseline in Morning Pre-dose Trough FEV1 (L) at Week 24

    Change from baseline in morning pre-dose trough FEV1 at Week 24. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Week 24

  2. Onset of Action on Day 1: Absolute Change in FEV1 (L) at 5 Minutes on Day 1

    Onset of action on Day 1: Absolute change in FEV1 (L) at 5 minutes on Day 1. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Day 1

  3. Percentage of Responders in ACQ-7 (≥0.5 Decrease Equals Response) at Week 24

    Percentage of responders in Asthma Control Questionnaire (ACQ)-7 (≥0.5 decrease equals response) at Week 24. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Week 24

  4. Percentage of Responders in ACQ-5 (≥0.5 Decrease Equals Response) at Week 24

    Percentage of responders in ACQ-5 (≥0.5 decrease equals response) at Week 24. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Week 24

  5. Percentage of Responders in AQLQ(s) +12 (≥0.5 Increase Equals Response) at Week 24

    Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ\[s\]) +12 (≥0.5 increase equals response) at Week 24. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Week 24

  6. Percentage of Responders in SGRQ (≥4.0 Decrease Equals Response) at Week 24

    Percentage of responders in the St. George's Respiratory Questionnaire (SGRQ) (≥4.0 decrease equals response) at Week 24. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Week 24

  7. Pooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations for Participants With Percent Predicted FEV1 ≤55% at Baseline

    Rate of severe asthma exacerbations for participants with percent predicted FEV1 ≤55% at baseline was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). An asthma exacerbation was severe if it resulted in at least 1 of the following: systemic corticosteroids for 3 days, an ER/urgent care visit requiring systemic corticosteroids, a hospitalization, or death related to asthma. Consecutive exacerbations with start/stop days ≤7 days apart were considered the same event. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Up to 52 Weeks

  8. Pooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations for Participants With ≥1 Severe Exacerbation in the 12 Months Prior to Visit 1

    Rate of severe asthma exacerbations for participants with ≥1 severe exacerbation in the 12 months prior to Visit 1 was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). An asthma exacerbation was severe if it resulted in at least 1 of the following: systemic corticosteroids for 3 days, an ER/urgent care visit requiring systemic corticosteroids, a hospitalization, or death related to asthma. Consecutive exacerbations with start/stop days ≤7 days apart were considered the same event. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Up to 52 Weeks

  9. Pooled (LOGOS/KALOS): Time to First Severe Asthma Exacerbation

    Time to first severe asthma exacerbation was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). Time to first severe asthma exacerbation was the time from the first dose of study medication to the time of onset of the first severe asthma exacerbation. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Up to 52 weeks

  10. Pooled (LOGOS/KALOS): Rate of Moderate or Severe Asthma Exacerbations

    Rate of moderate/severe exacerbations was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). An exacerbation was severe if it resulted in at least 1 of the following: systemic corticosteroids for 3 days, an ER/urgent care visit requiring systemic corticosteroids, an inpatient hospitalization, or death related to asthma. A moderate exacerbation was a worsening of symptoms that resulted in additional ICS for 3 days. Consecutive exacerbations with start/stop days ≤7 days apart were considered the same event. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Up to 52 Weeks

  11. Pooled (LOGOS/KALOS): Time to First Moderate or Severe Asthma Exacerbation

    Time to first moderate/severe asthma exacerbation was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). Time to first moderate or severe asthma exacerbation was the time from the first dose of study medication to the time of onset of the first moderate/severe asthma exacerbation. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Up to 52 weeks

  12. Pooled (LOGOS/KALOS): Percentage of Responders in ACQ-7 (≥0.5 Decrease Equals Response) at Week 24

    Percentage of responders in ACQ-7 (≥0.5 decrease equals response) at Week 24 was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Week 24

  13. Pooled (LOGOS/KALOS): Percentage of Responders in ACQ-5 (≥0.5 Decrease Equals Response) at Week 24

    Percentage of responders in ACQ-5 (≥0.5 decrease equals response) at Week 24 was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Week 24

  14. Pooled (LOGOS/KALOS): Percentage of Responders in AQLQ(s) +12 (≥0.5 Increase Equals Response) at Week 24

    Percentage of responders in AQLQ(s) +12 (≥0.5 increase equals response) at Week 24 was assessed in a pre- specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

    Time frame: Week 24

07

Results

Posted Jul 2, 2026
Limitations and caveats
The study was conducted during the SARS-CoV-2 pandemic, resulting in recruitment difficulties. As such, protocol amendments were instituted to facilitate recruitment, including removal of history of exacerbation criterion and terminating recruitment to the BGF MDI 320/14.4/9.6 μg treatment group.

Participant flow

A total of 2187 subjects were randomized at 324 study centers in 15 countries from 01 March 2021. The last subject completed their last study visit on 20 March 2025. Of the 2187 randomized subjects, all populations excluded 16 subjects due to GCP violations and 4 subjects due to not receiving study therapy.

Participant flow — Overall Study
MilestoneBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Started384585604594
Completed360535540544
Not completed24506450
Withdrew: Withdrawal by subject13293632
Withdrew: Adverse event4521
Withdrew: Lost to follow-up1267
Withdrew: Reasons not specified3461
Withdrew: Lack of efficacy1271
Withdrew: Physician decision1223
Withdrew: Pregnancy0201
Withdrew: Death0331
Withdrew: Development of study-specific criteria1000
Withdrew: Other0001
Withdrew: Non-compliance with study drug0122

Outcome measures

PrimaryChange From Baseline in FEV1 AUC0-3 (L) at Week 24

Change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24. Treatment policy was implemented to handle all intercurrent events (ICEs) with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Week 24
Reported as:
Least squares mean · Liters
Change From Baseline in FEV1 AUC0-3 (L) at Week 24
LitersBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Change From Baseline in FEV1 AUC0-3 (L) at Week 240.374 ± 0.0190.354 ± 0.0150.219 ± 0.0150.239 ± 0.015
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · ANCOVA · p = <0.001 · Ls mean difference: 0.155 · 95% CI 0.109 to 0.201An increase in estimate for comparison favors study drug. Subject number analyzed based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · ANCOVA · p = <0.001 · Ls mean difference: 0.134 · 95% CI 0.093 to 0.175An increase in estimate for comparison favors study drug. Subject number analyzed based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
PrimaryPooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations

Rate of severe asthma exacerbations was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). An asthma exacerbation was severe if it resulted in at least 1 of the following: systemic corticosteroids for 3 days, an ER/urgent care visit requiring systemic corticosteroids, a hospitalization, or death related to asthma. Consecutive exacerbations with start/stop days ≤7 days apart were considered the same event. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Up to 52 Weeks
Reported as:
Number · Exacerbations/Subject Years
Pooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations
Exacerbations/Subject YearsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Pooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations0.5330.5410.6040.662
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Negative binomial regression · p = 0.120 · Rate ratio: 0.882 · 95% CI 0.754 to 1.033A rate ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Negative binomial regression · p = 0.124 · Rate ratio: 0.896 · 95% CI 0.779 to 1.031A rate ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryChange From Baseline in Morning Pre-dose Trough FEV1 (L) at Week 24

Change from baseline in morning pre-dose trough FEV1 at Week 24. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Week 24
Reported as:
Least squares mean · Liters
Change From Baseline in Morning Pre-dose Trough FEV1 (L) at Week 24
LitersBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Change From Baseline in Morning Pre-dose Trough FEV1 (L) at Week 240.186 ± 0.0180.177 ± 0.0150.069 ± 0.0140.085 ± 0.015
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · ANCOVA · p = <0.001 · Ls mean difference: 0.117 · 95% CI 0.073 to 0.161An increase in estimate for comparison favors study drug. Subject number analyzed based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · ANCOVA · p = <0.001 · Ls mean difference: 0.107 · 95% CI 0.068 to 0.147An increase in estimate for comparison favors study drug. Subject number analyzed based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryOnset of Action on Day 1: Absolute Change in FEV1 (L) at 5 Minutes on Day 1

Onset of action on Day 1: Absolute change in FEV1 (L) at 5 minutes on Day 1. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Day 1
Reported as:
Mean · Liters
Onset of Action on Day 1: Absolute Change in FEV1 (L) at 5 Minutes on Day 1
LitersBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Onset of Action on Day 1: Absolute Change in FEV1 (L) at 5 Minutes on Day 10.155 ± 0.2110.180 ± 0.2110.134 ± 0.2020.143 ± 0.202
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID · t-test, 1 sided · p = <0.001 · Within bgf mdi group t-test estimate: 0.155 · 95% CI 0.133 to 0.177Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing value at the visit were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID · t-test, 1 sided · p = <0.001 · Within bgf mdi group t-test estimate: 0.180 · 95% CI 0.162 to 0.197Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing value at the visit were included in the analysis.
SecondaryPercentage of Responders in ACQ-7 (≥0.5 Decrease Equals Response) at Week 24

Percentage of responders in Asthma Control Questionnaire (ACQ)-7 (≥0.5 decrease equals response) at Week 24. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Percentage of Responders in ACQ-7 (≥0.5 Decrease Equals Response) at Week 24
ParticipantsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Percentage of Responders in ACQ-7 (≥0.5 Decrease Equals Response) at Week 24251371360351
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.076 · Odds ratio (or): 1.29 · 95% CI 0.97 to 1.72An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.067 · Odds ratio (or): 1.27 · 95% CI 0.98 to 1.63An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPercentage of Responders in ACQ-5 (≥0.5 Decrease Equals Response) at Week 24

Percentage of responders in ACQ-5 (≥0.5 decrease equals response) at Week 24. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Percentage of Responders in ACQ-5 (≥0.5 Decrease Equals Response) at Week 24
ParticipantsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Percentage of Responders in ACQ-5 (≥0.5 Decrease Equals Response) at Week 24263388387380
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.159 · Odds ratio (or): 1.23 · 95% CI 0.92 to 1.66An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.190 · Odds ratio (or): 1.19 · 95% CI 0.92 to 1.54An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPercentage of Responders in AQLQ(s) +12 (≥0.5 Increase Equals Response) at Week 24

Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ\[s\]) +12 (≥0.5 increase equals response) at Week 24. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Percentage of Responders in AQLQ(s) +12 (≥0.5 Increase Equals Response) at Week 24
ParticipantsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Percentage of Responders in AQLQ(s) +12 (≥0.5 Increase Equals Response) at Week 24205297301289
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.546 · Odds ratio (or): 1.09 · 95% CI 0.82 to 1.45An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Linear · p = 0.312 · Odds ratio (or): 1.14 · 95% CI 0.88 to 1.47An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPercentage of Responders in SGRQ (≥4.0 Decrease Equals Response) at Week 24

Percentage of responders in the St. George's Respiratory Questionnaire (SGRQ) (≥4.0 decrease equals response) at Week 24. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Percentage of Responders in SGRQ (≥4.0 Decrease Equals Response) at Week 24
ParticipantsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Percentage of Responders in SGRQ (≥4.0 Decrease Equals Response) at Week 24229329336344
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.464 · Odds ratio (or): 1.11 · 95% CI 0.83 to 1.49An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.556 · Odds ratio (or): 1.08 · 95% CI 0.84 to 1.40An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations for Participants With Percent Predicted FEV1 ≤55% at Baseline

Rate of severe asthma exacerbations for participants with percent predicted FEV1 ≤55% at baseline was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). An asthma exacerbation was severe if it resulted in at least 1 of the following: systemic corticosteroids for 3 days, an ER/urgent care visit requiring systemic corticosteroids, a hospitalization, or death related to asthma. Consecutive exacerbations with start/stop days ≤7 days apart were considered the same event. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Up to 52 Weeks
Reported as:
Number · Exacerbations/Subject Years
Pooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations for Participants With Percent Predicted FEV1 ≤55% at Baseline
Exacerbations/Subject YearsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Pooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations for Participants With Percent Predicted FEV1 ≤55% at Baseline0.7330.6630.7800.815
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Negative binomial regression · p = 0.620 · Rate ratio: 0.940 · 95% CI 0.736 to 1.200A rate ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Negative binomial regression · p = 0.146 · Rate ratio: 0.850 · 95% CI 0.682 to 1.058A rate ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations for Participants With ≥1 Severe Exacerbation in the 12 Months Prior to Visit 1

Rate of severe asthma exacerbations for participants with ≥1 severe exacerbation in the 12 months prior to Visit 1 was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). An asthma exacerbation was severe if it resulted in at least 1 of the following: systemic corticosteroids for 3 days, an ER/urgent care visit requiring systemic corticosteroids, a hospitalization, or death related to asthma. Consecutive exacerbations with start/stop days ≤7 days apart were considered the same event. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Up to 52 Weeks
Reported as:
Number · Exacerbations/Subject Years
Pooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations for Participants With ≥1 Severe Exacerbation in the 12 Months Prior to Visit 1
Exacerbations/Subject YearsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Pooled (LOGOS/KALOS): Rate of Severe Asthma Exacerbations for Participants With ≥1 Severe Exacerbation in the 12 Months Prior to Visit 10.7070.6530.7100.805
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Negative binomial regression · p = 0.970 · Rate ratio: 0.996 · 95% CI 0.826 to 1.202A rate ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Negative binomial regression · p = 0.354 · Rate ratio: 0.921 · 95% CI 0.773 to 1.097A rate ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPooled (LOGOS/KALOS): Time to First Severe Asthma Exacerbation

Time to first severe asthma exacerbation was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). Time to first severe asthma exacerbation was the time from the first dose of study medication to the time of onset of the first severe asthma exacerbation. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Up to 52 weeks
Reported as:
Number · Percentage of participants
Pooled (LOGOS/KALOS): Time to First Severe Asthma Exacerbation
Percentage of participantsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Kaplan-Meier estimate at 24 weeks (%)18.918.620.822.3
Kaplan-Meier estimate at 52 weeks (%)36.035.539.241.5
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Cox · p = 0.145 (Endpoint not included in the Type I error control procedure.) · Hazard ratio (hr): 0.892 · 95% CI 0.765 to 1.040A hazard ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Cox · p = 0.061 (Endpoint not included in the Type I error control procedure.) · Hazard ratio (hr): 0.879 · 95% CI 0.767 to 1.006A hazard ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPooled (LOGOS/KALOS): Rate of Moderate or Severe Asthma Exacerbations

Rate of moderate/severe exacerbations was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). An exacerbation was severe if it resulted in at least 1 of the following: systemic corticosteroids for 3 days, an ER/urgent care visit requiring systemic corticosteroids, an inpatient hospitalization, or death related to asthma. A moderate exacerbation was a worsening of symptoms that resulted in additional ICS for 3 days. Consecutive exacerbations with start/stop days ≤7 days apart were considered the same event. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Up to 52 Weeks
Reported as:
Number · Exacerbations/Subject Years
Pooled (LOGOS/KALOS): Rate of Moderate or Severe Asthma Exacerbations
Exacerbations/Subject YearsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Pooled (LOGOS/KALOS): Rate of Moderate or Severe Asthma Exacerbations0.5450.5550.6260.680
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Negative binomial regression · p = 0.079 (Endpoint not included in the Type I error control procedure.) · Rate ratio: 0.869 · 95% CI 0.744 to 1.016A rate ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Negative binomial regression · p = 0.088 (Endpoint not included in the Type I error control procedure.) · Rate ratio: 0.886 · 95% CI 0.772 to 1.018A rate ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPooled (LOGOS/KALOS): Time to First Moderate or Severe Asthma Exacerbation

Time to first moderate/severe asthma exacerbation was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). Time to first moderate or severe asthma exacerbation was the time from the first dose of study medication to the time of onset of the first moderate/severe asthma exacerbation. Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Up to 52 weeks
Reported as:
Number · Percentage of participants
Pooled (LOGOS/KALOS): Time to First Moderate or Severe Asthma Exacerbation
Percentage of participantsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Kaplan-Meier estimate at 24 weeks (%)19.119.121.422.9
Kaplan-Meier estimate at 52 weeks (%)36.336.240.042.3
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Cox · p = 0.097 (Endpoint not included in the Type I error control procedure.) · Hazard ratio (hr): 0.878 · 95% CI 0.754 to 1.024A hazard ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Cox · p = 0.055 (Endpoint not included in the Type I error control procedure.) · Hazard ratio (hr): 0.877 · 95% CI 0.767 to 1.003A hazard ratio below 1 favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects who were randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPooled (LOGOS/KALOS): Percentage of Responders in ACQ-7 (≥0.5 Decrease Equals Response) at Week 24

Percentage of responders in ACQ-7 (≥0.5 decrease equals response) at Week 24 was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Pooled (LOGOS/KALOS): Percentage of Responders in ACQ-7 (≥0.5 Decrease Equals Response) at Week 24
ParticipantsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Pooled (LOGOS/KALOS): Percentage of Responders in ACQ-7 (≥0.5 Decrease Equals Response) at Week 24458741733693
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.215 (Endpoint not included in the Type I error control procedure.) · Odds ratio (or): 1.14 · 95% CI 0.93 to 1.39An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.123 (Endpoint not included in the Type I error control procedure.) · Odds ratio (or): 1.15 · 95% CI 0.96 to 1.37An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPooled (LOGOS/KALOS): Percentage of Responders in ACQ-5 (≥0.5 Decrease Equals Response) at Week 24

Percentage of responders in ACQ-5 (≥0.5 decrease equals response) at Week 24 was assessed in a pre-specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Pooled (LOGOS/KALOS): Percentage of Responders in ACQ-5 (≥0.5 Decrease Equals Response) at Week 24
ParticipantsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Pooled (LOGOS/KALOS): Percentage of Responders in ACQ-5 (≥0.5 Decrease Equals Response) at Week 24486769781741
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.170 (Endpoint not included in the Type I error control procedure.) · Odds ratio (or): 1.16 · 95% CI 0.94 to 1.42An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.444 (Endpoint not included in the Type I error control procedure.) · Odds ratio (or): 1.07 · 95% CI 0.90 to 1.28An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
SecondaryPooled (LOGOS/KALOS): Percentage of Responders in AQLQ(s) +12 (≥0.5 Increase Equals Response) at Week 24

Percentage of responders in AQLQ(s) +12 (≥0.5 increase equals response) at Week 24 was assessed in a pre- specified pooled analysis across replicate studies D5982C00008 and D5982C00007 (NCT04609878). Treatment policy was implemented to handle all ICEs with the exception of initiation of new asthma therapy or use of prohibited medications thought to impact efficacy in conjunction with premature discontinuation of study intervention, for which the composite strategy was implemented.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Pooled (LOGOS/KALOS): Percentage of Responders in AQLQ(s) +12 (≥0.5 Increase Equals Response) at Week 24
ParticipantsBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Pooled (LOGOS/KALOS): Percentage of Responders in AQLQ(s) +12 (≥0.5 Increase Equals Response) at Week 24376588593568
Statistical analysis
  • BGF MDI 320/14.4/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Logistic · p = 0.539 (Endpoint not included in the Type I error control procedure.) · Odds ratio (or): 1.07 · 95% CI 0.87 to 1.30An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.
  • BGF MDI 320/28.8/9.6 μg BID vs BFF MDI 320/9.6 μg BID · Regression, Linear · p = 0.398 (Endpoint not included in the Type I error control procedure.) · Odds ratio (or): 1.08 · 95% CI 0.90 to 1.29An odds ratio \>1 for comparison favors study drug. Number of subjects analyzed is based on the Efficacy Set, which excluded 7 subjects randomized across multiple Sponsor studies. Only subjects with nonmissing covariates were included in the analysis.

Adverse events

Collected over Up to 52 Weeks with a 2-week safety follow-up period; adverse events were collected from first intake of study intervention after Visit 1, during screening and throughout the Treatment Period and including the follow-up period. "All-Cause Mortality" events are presented for the on-study period and SAEs are presented for the on-treatment period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BGF MDI 320/14.4/9.6 μg BID0/384 (0%)31/384 (8.1%)122/384 (31.8%)
BGF MDI 320/28.8/9.6 μg BID3/585 (0.5%)41/585 (7%)157/585 (26.8%)
BFF MDI 320/9.6 μg BID3/604 (0.5%)49/604 (8.1%)169/604 (28%)
Symbicort® 320/9 μg BID1/594 (0.2%)36/594 (6.1%)162/594 (27.3%)
Most frequent serious events
Showing 10 of 104
Most frequent serious events
EventBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
AsthmaRespiratory, thoracic and mediastinal disorders7/38414/58520/60413/594
PneumoniaInfections and infestations4/3844/5851/6044/594
Nasal PolypsRespiratory, thoracic and mediastinal disorders0/3842/5853/6040/594
Cerebral infarctionNervous system disorders0/3840/5853/6040/594
COVID-19 PneumoniaInfections and infestations0/3842/5850/6041/594
Arteriosclerosis coronary arteryCardiac disorders0/3840/5851/6042/594
CholelithiasisHepatobiliary disorders0/3840/5851/6042/594
SinusitisInfections and infestations0/3840/5850/6042/594
CataractEye disorders1/3840/5852/6040/594
MigraineNervous system disorders0/3840/5852/6040/594
Most frequent other events
Most frequent other events
EventBGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BID
Upper respiratory tract infectionInfections and infestations58/38474/58593/60483/594
NasopharyngitisInfections and infestations46/38462/58551/60461/594
COVID-19Infections and infestations29/38443/58538/60438/594

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BIDTotal
Age group (years) — <=18 years914171858
Age group (years) — Between 18 and 65 years3124474774511687
Age group (years) — >=65 years63124110125422
Sex: Female, Male
Sex: Female, Male(Participants)BGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BIDTotal
Sex — Female2243413833701318
Sex — Male160244221224849
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BIDTotal
Ethnicity — Hispanic or Latino40716860239
Ethnicity — Not Hispanic or Latino3445145365341928
Ethnicity — Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BIDTotal
Race — American Indian or Alaska Native975930
Race — Asian170222230231853
Race — Native Hawaiian or Other Pacific Islander00101
Race — Black or African American11353530111
Race — White150268270264952
Race — More than one race00000
Race — Unknown or Not Reported44536360220
Region of Enrollment
Region of Enrollment(Participants)BGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BIDTotal
Brazil1125252081
China156210214215795
Colombia01113
Czech Republic25333435127
Germany28535659196
United Kingdom00415
Greece412121341
Israel1122232682
Mexico27333231123
Portugal156214
Russia2224252495
Slovakia1219211870
South Africa60807778295
Turkey2891029
United States25606561211
Baseline Reversibility (%)
Baseline Reversibility (%)(Percentage)BGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BIDTotal
Mean22.3 ± 18.121.7 ± 17.921.6 ± 17.222.0 ± 17.521.9 ± 17.6
Baseline Pre-bronchodilator Percent Predicted FEV1 (%)
Baseline Pre-bronchodilator Percent Predicted FEV1 (%)(Percentage)BGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BIDTotal
Mean58.6 ± 12.257.9 ± 13.359.6 ± 12.459.3 ± 12.458.9 ± 12.6
Baseline Severe Asthma Exacerbation History Within the Prior Year
Baseline Severe Asthma Exacerbation History Within the Prior Year(Participants)BGF MDI 320/14.4/9.6 μg BIDBGF MDI 320/28.8/9.6 μg BIDBFF MDI 320/9.6 μg BIDSymbicort® 320/9 μg BIDTotal
0 exacerbations1703103113021093
1 exacerbation173225234235867
≥2 exacerbations40505753200

1 further baseline measures are reported on the registry.

08

Study locations

317 sites
  • Research Site
    Chandler, Arizona 85224, United States
  • Research Site
    Tempe, Arizona 85283, United States
  • Research Site
    Tucson, Arizona 85741, United States
  • Research Site
    Hot Springs, Arkansas 71913, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Carlsbad, California 92008, United States
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    Lancaster, California 93534, United States
  • Research Site
    Long Beach, California 90815, United States
  • Research Site
    Mission Viejo, California 92691, United States
  • Research Site
    North Hollywood, California 91606, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Rancho Cucamonga, California 91730, United States
  • Research Site
    Sacramento, California 95823, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    San Jose, California 95117, United States
  • Research Site
    Ventura, California 93003, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Colorado Springs, Colorado 80910, United States
  • Research Site
    Wheat Ridge, Colorado 80033, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Boca Raton, Florida 33487, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    Cutler Bay, Florida 33189, United States
  • Research Site
    DeBary, Florida 32713, United States
  • Research Site
    Hialeah, Florida 33016, United States
  • Research Site
    Lakeland, Florida 33813, United States
  • Research Site
    Miami, Florida 33135, United States
  • Research Site
    Tampa, Florida 33615, United States
  • Research Site
    Acworth, Georgia 30101, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Atlanta, Georgia 30350, United States
  • Research Site
    Snellville, Georgia 30078, United States
  • Research Site
    Boise, Idaho 83706, United States
  • Research Site
    Chicago, Illinois 60621, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Peoria, Illinois 61636, United States
  • Research Site
    Evansville, Indiana 47715, United States
  • Research Site
    Marrero, Louisiana 70072, United States
  • Research Site
    Zachary, Louisiana 70791, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    White Marsh, Maryland 21162, United States
  • Research Site
    Fall River, Massachusetts 02723, United States
  • Research Site
    Farmington Hills, Michigan 48336, United States
  • Research Site
    Rochester, Michigan 48307, United States
  • Research Site
    Troy, Michigan 48085, United States
  • Research Site
    St Louis, Missouri 63141, United States
  • Research Site
    Warrensburg, Missouri 64093, United States
  • Research Site
    North Las Vegas, Nevada 89030, United States
  • Research Site
    Portsmouth, New Hampshire 03801, United States
  • Research Site
    Ocean City, New Jersey 07712, United States
  • Research Site
    Albuquerque, New Mexico 87102, United States
  • Research Site
    Brooklyn, New York 11236, United States
  • Research Site
    The Bronx, New York 10459, United States
  • Research Site
    The Bronx, New York 10461, United States
  • Research Site
    The Bronx, New York 10468, United States
  • Research Site
    Greensboro, North Carolina 27405, United States
  • Research Site
    Huntersville, North Carolina 28078, United States
  • Research Site
    Monroe, North Carolina 28112, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Portland, Oregon 97202, United States
  • Research Site
    Jenkintown, Pennsylvania 19046, United States
  • Research Site
    Philadelphia, Pennsylvania 19107, United States
  • Research Site
    Spartanburg, South Carolina 29303, United States
  • Research Site
    Knoxville, Tennessee 37909, United States
  • Research Site
    Amarillo, Texas 79106, United States
  • Research Site
    Cedar Park, Texas 78613, United States
  • Research Site
    Dallas, Texas 75254, United States
  • Research Site
    Denison, Texas 75020, United States
  • Research Site
    Forney, Texas 75126, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    Lewisville, Texas 75067, United States
  • Research Site
    McKinney, Texas 75069, United States
  • Research Site
    North Richland Hills, Texas 76180, United States
  • Research Site
    Pearland, Texas 77584, United States
  • Research Site
    Plano, Texas 75093, United States
  • Research Site
    San Antonio, Texas 78258, United States
  • Research Site
    Sugar Land, Texas 77478, United States
  • Research Site
    Victoria, Texas 77901, United States
  • Research Site
    Roy, Utah 84067, United States
  • Research Site
    Abingdon, Virginia 24210, United States
  • Research Site
    Burke, Virginia 22015, United States
  • Research Site
    Williamsburg, Virginia 23188, United States
  • Research Site
    Milwaukee, Wisconsin 53226, United States
  • Research Site
    Milwaukee, Wisconsin 53228, United States
  • Research Site
    Botucatu, 18618-970, Brazil
  • Research Site
    Porto Alegre, 9002-060, Brazil
  • Research Site
    Porto Alegre, 90430-001, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    Santo André, 09080-110, Brazil
  • Research Site
    São Paulo, 05403-000, Brazil
  • Research Site
    Sorocaba, 18040-425, Brazil
  • Research Site
    Baotou, 014010, China
  • Research Site
    Beijing, 100020, China
  • Research Site
    Changsha, 410005, China
  • Research Site
    Changsha, 410008, China

Showing the first 100 of 317 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Papi A, Wise RA, Jackson DJ, Lugogo N, Chen R, Trasieva T, Obasi C, Movitz C, Helman J, Salter P, Springer K, Bondoc M, Shah M, Knappenberger K, Bowen K, Pandya H, Megally A, Patel M; KALOS and LOGOS study investigators. Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. Lancet Respir Med. 2026 Apr;14(4):350-362. doi: 10.1016/S2213-2600(25)00457-6. Epub 2026 Feb 12. PubMed 41692019 ↗
  • Oba Y, Anwer S, Maduke T, Patel T, Dias S. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2022 Dec 6;12(12):CD013799. doi: 10.1002/14651858.CD013799.pub2. PubMed 36472162 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Mar 2025, 48 months.

Results were first posted in Jul 2026, 1 year 3 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 48 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Oct 30, 2020
StartActual
Mar 1, 2021
Primary completionActual
Mar 20, 2025
CompletionActual
Mar 20, 2025
Results first posted
Jul 2, 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04609904
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 30, 2020
Start date
Mar 1, 2021
Primary completion
Mar 20, 2025
Completion
Mar 20, 2025
Results posted
Jul 2, 2026
Last update
Jul 2, 2026

Study contacts

Robert Wise, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budesonide · Glycopyrrolate · Formoterol

Start the discussion